Genomic diagnostics company GC Genome has announced the results of a study that proved the ability of its liquid biopsy technology to predict radiation therapy (RT) response in solid tumours.
The trial showed the feasibility of cell-free DNA (cfDNA) monitoring for the prediction of treatment response and the identification of minimal residual disease after RT in solid tumour patients using the I-score tool.
